Study on the Safety of the New Radial Artery Hemostasis Device
Table 1
Baseline characteristics between the two groups.
Variable
CD group (n = 30)
TR group (n = 30)
χ2/t
-value
Age
59.20 ± 9.35
56.90 ± 10.52
0.895
0.374
Male
17 (56.67)
18 (60.00)
0.069
0.793
Height, cm
167.15 ± 7.94
165.77 ± 6.92
−0.719
0.475
Weight, kg
70.73 ± 11.48
66.95 ± 11.02
−1.303
0.198
BMI, kg/m2
24.34 ± 3.79
25.28 ± 3.45
−0.979
0.332
Hypertension
13 (43.33)
18 (60.00)
1.669
0.196
Diabetes
3 (10.00)
5 (16.67)
0.577
0.706
Hyperlipidemia
18 (60.00)
15 (50.00)
0.606
0.436
Chronic renal failure
0 (0.00)
1 (3.30)
0.000
1.000
Family history of CAD
5 (16.67)
9 (30.00)
1.491
0.222
Smoking
12 (40.00)
14 (46.67)
0.271
0.602
Platelet count, ×10^9/L
224.70 ± 97.58
228.33 ± 51.58
−0.180
0.858
PT, s
11.78 ± 0.95
11.75 ± 1.41
0.075
0.940
APTT, s
29.16 ± 13.02
26.27 ± 5.00
1.132
0.262
PT. INR
1.00 ± 0.09
1.00 ± 0.07
−0.065
0.948
Creatinine, μmol/L
68.39 ± 17.60
67.43 ± 12.77
0.242
0.810
Clopidogrel
2 (6.67)
0 (0.00)
2.069
0.492
Aspirin
3 (10.00)
5 (16.67)
0.577
0.706
Procedure characteristics
Sheath size (5 French)
29 (96.67)
30 (100.00)
1.017
1.000
Heparin used during procedure, IU
3166.67 ± 647.72
3083.33 ± 323.86
0.630
0.531
Procedure time, min
25.57 ± 8.76
26.77 ± 6.25
−0.611
0.544
CAG
28 (93.33)
28 (93.33)
0.000
1.000
Values are presented as mean ± standard deviation or n (%). BMI, body mass index; PT, prothrombin time; APTT, activated partial thromboplastin time; PT. INR, prothrombin time international normalized ratio.
